TY  - JOUR
T1  - POstherpetic neuralgia in herpes zoster—reply
AU  - Whitley RJ
Y1  - 2009/11/04
N1  - 10.1001/jama.2009.1581
JO  - JAMA
SP  - 1862
EP  - 1863
VL  - 302
IS  - 17
N2  - 
I stand by my statement that “[p]revention of PHN is a major concern because antiviral drugs alone do not reliably prevent this complication.” The US Food and Drug Administration (FDA), using the definition of PHN cited by Zhou et al, concluded that although treatment may decrease the median duration of pain (as a continuum), the data from well-controlled clinical trials did not provide evidence of reduction of PHN for any of the licensed drugs: acyclovir,1 valacyclovir,2 or famciclovir.3 The FDA refused to grant this indication based on its analyses and input from advisory committees.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2009.1581
UR  - http://dx.doi.org/10.1001/jama.2009.1581
ER  -